![Dicky To](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dicky To
Private Equity Investor bij
ORI Capital Investment Advisory Hong Kong Ltd.
Profiel
Dicky To is currently a Partner at ORI Capital Investment Advisory Hong Kong Ltd. He previously worked as a Managing Director & Partner at RSM Hong Kong.
Mr. To completed his undergraduate degree at the University of Hong Kong.
Actieve functies van Dicky To
| Bedrijven | Functie | Begin |
|---|---|---|
ORI Capital Investment Advisory Hong Kong Ltd.
 ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Private Equity Investor | 01-04-2019 |
Eerdere bekende functies van Dicky To
| Bedrijven | Functie | Einde |
|---|---|---|
RSM Hong Kong
 RSM Hong Kong Miscellaneous Commercial ServicesCommercial Services Provides accounting and consulting services | Corporate Officer/Principal | - |
Opleiding van Dicky To
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
1
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
RSM Hong Kong
RSM Hong Kong Miscellaneous Commercial ServicesCommercial Services Provides accounting and consulting services | Commercial Services |
University of Hong Kong
 University of Hong Kong Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Finance |
